A detailed history of Princeton Capital Management LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Princeton Capital Management LLC holds 13,420 shares of MRNA stock, worth $882,365. This represents 0.53% of its overall portfolio holdings.

Number of Shares
13,420
Previous 12,507 7.3%
Holding current value
$882,365
Previous $1.33 Million 19.59%
% of portfolio
0.53%
Previous 0.49%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$101.21 - $166.61 $92,404 - $152,114
913 Added 7.3%
13,420 $1.59 Million
Q1 2024

May 09, 2024

BUY
$85.37 - $115.44 $64,198 - $86,810
752 Added 6.4%
12,507 $1.33 Million
Q4 2023

Feb 08, 2024

SELL
$69.51 - $104.43 $195,740 - $294,074
-2,816 Reduced 19.33%
11,755 $1.17 Million
Q3 2023

Nov 13, 2023

BUY
$96.41 - $126.61 $144,904 - $190,294
1,503 Added 11.5%
14,571 $1.51 Million
Q2 2023

Aug 14, 2023

BUY
$118.5 - $160.53 $39,223 - $53,135
331 Added 2.6%
13,068 $1.59 Million
Q1 2023

May 01, 2023

SELL
$135.66 - $197.02 $36,763 - $53,392
-271 Reduced 2.08%
12,737 $1.96 Million
Q4 2022

Jan 31, 2023

BUY
$118.38 - $210.04 $355 - $630
3 Added 0.02%
13,008 $2.34 Million
Q3 2022

Nov 10, 2022

SELL
$118.07 - $194.18 $61,396 - $100,973
-520 Reduced 3.84%
13,005 $1.54 Million
Q2 2022

Aug 15, 2022

BUY
$117.13 - $176.59 $20,497 - $30,903
175 Added 1.31%
13,525 $1.93 Million
Q1 2022

May 11, 2022

BUY
$126.46 - $235.05 $100,535 - $186,864
795 Added 6.33%
13,350 $2.3 Million
Q4 2021

Feb 09, 2022

BUY
$225.82 - $368.51 $34,776 - $56,750
154 Added 1.24%
12,555 $3.19 Million
Q3 2021

Nov 10, 2021

BUY
$221.9 - $484.47 $29,068 - $63,465
131 Added 1.07%
12,401 $4.77 Million
Q2 2021

Aug 11, 2021

BUY
$129.91 - $234.98 $1.59 Million - $2.88 Million
12,270 New
12,270 $2.88 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $25.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Princeton Capital Management LLC Portfolio

Follow Princeton Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Princeton Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Princeton Capital Management LLC with notifications on news.